UnitedHealth Group (UNH) rallies to close up 9% on the day, having pushed into double digit gains earlier in the day.
The company opened 2026 with solid momentum, generating **$111.7 billion in revenue**, up 2% year over year, while adjusted EPS came in at **$7.23**, ahead of internal expectations. Performance was supported by stronger execution across all major segments, continued pricing discipline, and an improved member mix. The company also sharpened its strategic focus on the U.S. market by exiting international operations and refreshing nearly half of its top 100 leadership positions. Operational discipline was reflected in a consolidated **medical care ratio of 83.9%**, improving 90 basis points year over year.
UnitedHealthcare prioritised profitability and product stability over membership growth, delivering a **6.6% operating margin** despite membership declining to **49.1 million consumers**. Revenue still increased to **$86.3 billion**, driven by repricing actions across Medicare and Commercial plans to offset elevated but stable medical cost trends. Digital engagement continued to scale, with more than **73 million digital visits** during the quarter and 80% of customer interactions now handled through digital channels. The business also expanded support for rural providers through accelerated payments and selected prior authorisation exemptions.
Optum delivered **$63.7 billion in revenue** and now supports more than **122 million consumers** across its platforms. Optum Health continues to improve execution under a more disciplined value-based care model, serving over **4 million patients** in fully risk-based arrangements. Optum Rx added more than **800 new clients** and lowered contact-centre demand through AI-enabled self-service tools. Optum Insight is advancing its AI-first enterprise strategy and recently agreed to acquire **Alegeus Technologies** to strengthen consumer-directed healthcare financial services capabilities.
Technology remains central to the company’s transformation, with **$1.5 billion of AI-related investment** planned for 2026. Early benefits include a targeted **30% reduction in medical prior authorisations**, real-time processing for half of electronic requests, and prescription approval times at Optum Rx reduced from eight hours to under 30 seconds. These investments lifted the operating cost ratio to **13.8%**, though management expects margin benefits to build as productivity gains scale through the year.
Looking ahead, UnitedHealth raised its full-year adjusted EPS outlook to **above $18.25**, signalling confidence in continued operational progress. The company also plans at least **$2 billion in share repurchases** by the end of Q2, while reducing its debt-to-total capital ratio to **42.9%**, with a 40% year-end target. In parallel, it committed **$400 million** of proceeds from the UK business sale to the United Health Foundation to support rural healthcare access and workforce development.
The company beat lowered consensus expectations for its third quarter 2025 earnings and raised its full-year guidance, even though operating earnings fell sharply year over year.
The sharp drop in operating profit largely reflects persistently high medical costs, reduced Medicare funding, and competitive pressures in Medicaid and Medicare Advantage.
Despite these headwinds, the domestic insurance segment posted robust membership gains and Optum's pharmacy services contributed meaningfully.
Management acknowledges the Medicaid business will remain challenged through 2026, but expects a turnaround by 2027.
The company expressed optimism by raising its 2025 adjusted EPS outlook from $16.00 to at least $16.25 per share, and net earnings guidance from at least $14.50 to $14.90 per share.
We recently learned that Warren Buffet at Berkshire Hathaway has been investing in UnitedHealth, but other notable investors are also appearing on the share register.
UNH is now the second largest holding of David Tepper at Appaloosa Holdings (11.85% of his fund).
Even Michael Burry, made famous by the 'Big Short' movie which chronicled how he made billions by correctly calling the sub-prime crisis before it happened, has gained exposure to UNH through the options market via his Scion Asset Management vehicle.
UnitedHealth Group Second quarter 2025 earnings report undermines confidence.
The financial results show substantial pressure - with second quarter consolidated medical care ratio increasing 430 basis points year-over-year to 89.4%, resulting in earnings from operations declining from $7.9 billion in Q2 2024 to $5.2 billion in Q2 2025.
The medical care ratio (MCR) is a critical metric for health insurance companies that measures what percentage of premium revenue is spent on actual medical care for members. An 89.4% medical care ratio means that for every dollar UnitedHealth collected in premiums, they spent 89.4 cents on medical claims and care for their members. This leaves only 10.6 cents from each premium dollar to cover administrative costs, profits, and other expenses.
A 430 basis point move is huge. The company underestimated how much medical costs would rise when they set premium prices for 2025. The report notes that "medical cost trends which significantly exceeded pricing trends, including both unit costs and the intensity of services delivered"
However, the company's sentiment is cautiously optimistic despite facing significant short-term operational headwinds.
This is the part that investors seem to be missing. Health insurance operates on annual contract cycles, meaning UnitedHealth can completely reprice their policies every year based on updated medical cost trends, utilization patterns, and claims experience. When they face a year like 2025 with medical costs significantly exceeding expectations, they can adjust 2026 premiums to reflect these new realities (subject only to market competition and regulatory approval processes).
This is a structural advantage that health insurers like UnitedHealth have over other types of insurance companies, particularly life insurers (When a life insurer misprices mortality risk, investment returns, or expenses, they're typically locked into those pricing assumptions for 20-50+ years. They cannot simply raise premiums the following year to correct for adverse experience.)
This structural difference means UnitedHealth's current MCR deterioration, while painful, is largely confined to 2025.
Returning Group CEO Stephen Hemsley remarked that "UnitedHealth Group has embarked on a rigorous path back to being a high-performing company... we strengthen operating disciplines, positioning us for growth in 2026 and beyond."
Similarly, UnitedHealthcare CEO Tim Noel noted that "while we face challenges across our lines of business, we believe we can resolve these issues and recapture our earnings growth potential".
Does this mean that the significant dip in the share price as a result of short-term noise presents an interesting buying opportunity? I'll leave you to decide.
**UnitedHealth Under the Microscope: What's Really Going On?**
UnitedHealth Group (UHG) is no stranger to headlines or government scrutiny, but then the same could be said about any other uber-successful company: just ask Apple, Google or Microsoft for instance.
With a sprawling presence across insurance, medical care, pharmacy benefits, and health tech, UHG has become a central player in the American healthcare system. But that size and influence come with growing questions, especially from the Department of Justice (DOJ), which has increasingly taken a hard look at the company’s business practices.
One of the DOJ’s biggest concerns centers on UHG’s rapid-fire acquisition strategy. Through Optum, its healthcare services arm, the company has been buying up physician practices and other providers at a fast pace. Regulators worry that this vertical integration could give UHG too much control, making it harder for smaller providers to compete and possibly reducing options for patients. It’s not illegal to be big, of course, but when growth starts to squeeze out competition, antitrust questions aren’t far behind.
Another hot-button issue is Medicare Advantage, the government-backed insurance program that UHG dominates. There have been repeated allegations that UHG overstates how sick some patients are, a practice known as “upcoding.” This can lead to higher payments from the government and bigger profits for insurers. While these accusations are serious, to date the DOJ hasn’t been able to build a rock-solid case. In fact, UHG recently scored a legal win when a special master ruled against the government in a ~$2 billion overpayment dispute.
Then there’s the concern about data and market power. UHG’s acquisition of Change Healthcare set off alarm bells because it gave the company access to a massive trove of proprietary data on competitors and patients. The DOJ tried, but failed, to block the deal, arguing it would stifle innovation and give UHG an unfair edge. The government has also tried to halt UHG’s proposed acquisition of home health provider Amedisys for similar reasons. So far, those efforts haven’t succeeded, but they highlight just how closely regulators are watching.
There’s also growing chatter about whether UnitedHealthcare might be giving its Optum-owned providers an unfair leg up, offering them better reimbursement rates or steering more patients their way. If true, that kind of preferential treatment could squeeze out independent doctors and make local healthcare markets even more consolidated. Adding to the noise are a number of private lawsuits claiming that UHG and other major insurers are deliberately underpaying out-of-network providers to cut costs.
But it’s worth keeping perspective. The U.S. legal system is famously litigious, and class-action lawsuits, especially in healthcare, are nearly as common as hamburgers. The presence of legal action doesn’t necessarily mean there’s a strong case. So far, the DOJ hasn’t filed any formal antitrust charges in this area, which suggests that while the speculation is loud, the evidence may not be solid enough, at least not yet.
UHG has also been a target in several False Claims Act cases, where it’s been accused of not correcting inaccurate diagnosis codes that inflated government payments. While these cases continue to surface, UHG has successfully defended itself in some of the most high-profile ones, raising questions about the overall strength of the government’s arguments.
Whether any of these pressures lead to real legal consequences is still up in the air. But one thing is certain: UHG’s scale and influence mean it will remain at the center of the healthcare debate and under the watchful eye of regulators for the foreseeable future.
While opinions and speculation are easy to find, and it's clear that UnitedHealth Group is under an unusually bright spotlight, so far opinions and speculation is all that they are. The market has reacted to this negative sentiment - has the stock been oversold? Only time will tell.
The very fact that people are concerned about the size, scale and market dominance of UHG may in fact be good news for its shareholders - it certainly did Microsoft, Google and Apple no harm!
UnitedHealth Group (UNH) rallies to close up 9% on the day, having pushed into double digit gains earlier in the day.
The company opened 2026 with solid momentum, generating **$111.7 billion in revenue**, up 2% year over year, while adjusted EPS came in at **$7.23**, ahead of internal expectations. Performance was supported by stronger execution across all major segments, continued pricing discipline, and an improved member mix. The company also sharpened its strategic focus on the U.S. market by exiting international operations and refreshing nearly half of its top 100 leadership positions. Operational discipline was reflected in a consolidated **medical care ratio of 83.9%**, improving 90 basis points year over year.
UnitedHealthcare prioritised profitability and product stability over membership growth, delivering a **6.6% operating margin** despite membership declining to **49.1 million consumers**. Revenue still increased to **$86.3 billion**, driven by repricing actions across Medicare and Commercial plans to offset elevated but stable medical cost trends. Digital engagement continued to scale, with more than **73 million digital visits** during the quarter and 80% of customer interactions now handled through digital channels. The business also expanded support for rural providers through accelerated payments and selected prior authorisation exemptions.
Optum delivered **$63.7 billion in revenue** and now supports more than **122 million consumers** across its platforms. Optum Health continues to improve execution under a more disciplined value-based care model, serving over **4 million patients** in fully risk-based arrangements. Optum Rx added more than **800 new clients** and lowered contact-centre demand through AI-enabled self-service tools. Optum Insight is advancing its AI-first enterprise strategy and recently agreed to acquire **Alegeus Technologies** to strengthen consumer-directed healthcare financial services capabilities.
Technology remains central to the company’s transformation, with **$1.5 billion of AI-related investment** planned for 2026. Early benefits include a targeted **30% reduction in medical prior authorisations**, real-time processing for half of electronic requests, and prescription approval times at Optum Rx reduced from eight hours to under 30 seconds. These investments lifted the operating cost ratio to **13.8%**, though management expects margin benefits to build as productivity gains scale through the year.
Looking ahead, UnitedHealth raised its full-year adjusted EPS outlook to **above $18.25**, signalling confidence in continued operational progress. The company also plans at least **$2 billion in share repurchases** by the end of Q2, while reducing its debt-to-total capital ratio to **42.9%**, with a 40% year-end target. In parallel, it committed **$400 million** of proceeds from the UK business sale to the United Health Foundation to support rural healthcare access and workforce development.
UnitedHealth Group, Q3 2025 results
The company beat lowered consensus expectations for its third quarter 2025 earnings and raised its full-year guidance, even though operating earnings fell sharply year over year.
The sharp drop in operating profit largely reflects persistently high medical costs, reduced Medicare funding, and competitive pressures in Medicaid and Medicare Advantage.
Despite these headwinds, the domestic insurance segment posted robust membership gains and Optum's pharmacy services contributed meaningfully.
Management acknowledges the Medicaid business will remain challenged through 2026, but expects a turnaround by 2027.
The company expressed optimism by raising its 2025 adjusted EPS outlook from $16.00 to at least $16.25 per share, and net earnings guidance from at least $14.50 to $14.90 per share.
Q3 operating cash flow reached $5.9 billion, supporting confidence in future growth.
CEO Stephen Hemsley emphasized a refocus on performance and "durable and accelerating growth" for 2026 and beyond.
We recently learned that Warren Buffet at Berkshire Hathaway has been investing in UnitedHealth, but other notable investors are also appearing on the share register.
UNH is now the second largest holding of David Tepper at Appaloosa Holdings (11.85% of his fund).
Even Michael Burry, made famous by the 'Big Short' movie which chronicled how he made billions by correctly calling the sub-prime crisis before it happened, has gained exposure to UNH through the options market via his Scion Asset Management vehicle.
Would you bet against these people?
Berkshire Hathaway reveals a new stake in UnitedHealth Group (UNH) causing the shares to rally strongly at the open.
UnitedHealth Group Second quarter 2025 earnings report undermines confidence.
The financial results show substantial pressure - with second quarter consolidated medical care ratio increasing 430 basis points year-over-year to 89.4%, resulting in earnings from operations declining from $7.9 billion in Q2 2024 to $5.2 billion in Q2 2025.
The medical care ratio (MCR) is a critical metric for health insurance companies that measures what percentage of premium revenue is spent on actual medical care for members. An 89.4% medical care ratio means that for every dollar UnitedHealth collected in premiums, they spent 89.4 cents on medical claims and care for their members. This leaves only 10.6 cents from each premium dollar to cover administrative costs, profits, and other expenses.
A 430 basis point move is huge. The company underestimated how much medical costs would rise when they set premium prices for 2025. The report notes that "medical cost trends which significantly exceeded pricing trends, including both unit costs and the intensity of services delivered"
However, the company's sentiment is cautiously optimistic despite facing significant short-term operational headwinds.
This is the part that investors seem to be missing. Health insurance operates on annual contract cycles, meaning UnitedHealth can completely reprice their policies every year based on updated medical cost trends, utilization patterns, and claims experience. When they face a year like 2025 with medical costs significantly exceeding expectations, they can adjust 2026 premiums to reflect these new realities (subject only to market competition and regulatory approval processes).
This is a structural advantage that health insurers like UnitedHealth have over other types of insurance companies, particularly life insurers (When a life insurer misprices mortality risk, investment returns, or expenses, they're typically locked into those pricing assumptions for 20-50+ years. They cannot simply raise premiums the following year to correct for adverse experience.)
This structural difference means UnitedHealth's current MCR deterioration, while painful, is largely confined to 2025.
Returning Group CEO Stephen Hemsley remarked that "UnitedHealth Group has embarked on a rigorous path back to being a high-performing company... we strengthen operating disciplines, positioning us for growth in 2026 and beyond."
Similarly, UnitedHealthcare CEO Tim Noel noted that "while we face challenges across our lines of business, we believe we can resolve these issues and recapture our earnings growth potential".
Does this mean that the significant dip in the share price as a result of short-term noise presents an interesting buying opportunity? I'll leave you to decide.
**UnitedHealth Under the Microscope: What's Really Going On?**
UnitedHealth Group (UHG) is no stranger to headlines or government scrutiny, but then the same could be said about any other uber-successful company: just ask Apple, Google or Microsoft for instance.
With a sprawling presence across insurance, medical care, pharmacy benefits, and health tech, UHG has become a central player in the American healthcare system. But that size and influence come with growing questions, especially from the Department of Justice (DOJ), which has increasingly taken a hard look at the company’s business practices.
One of the DOJ’s biggest concerns centers on UHG’s rapid-fire acquisition strategy. Through Optum, its healthcare services arm, the company has been buying up physician practices and other providers at a fast pace. Regulators worry that this vertical integration could give UHG too much control, making it harder for smaller providers to compete and possibly reducing options for patients. It’s not illegal to be big, of course, but when growth starts to squeeze out competition, antitrust questions aren’t far behind.
Another hot-button issue is Medicare Advantage, the government-backed insurance program that UHG dominates. There have been repeated allegations that UHG overstates how sick some patients are, a practice known as “upcoding.” This can lead to higher payments from the government and bigger profits for insurers. While these accusations are serious, to date the DOJ hasn’t been able to build a rock-solid case. In fact, UHG recently scored a legal win when a special master ruled against the government in a ~$2 billion overpayment dispute.
Then there’s the concern about data and market power. UHG’s acquisition of Change Healthcare set off alarm bells because it gave the company access to a massive trove of proprietary data on competitors and patients. The DOJ tried, but failed, to block the deal, arguing it would stifle innovation and give UHG an unfair edge. The government has also tried to halt UHG’s proposed acquisition of home health provider Amedisys for similar reasons. So far, those efforts haven’t succeeded, but they highlight just how closely regulators are watching.
There’s also growing chatter about whether UnitedHealthcare might be giving its Optum-owned providers an unfair leg up, offering them better reimbursement rates or steering more patients their way. If true, that kind of preferential treatment could squeeze out independent doctors and make local healthcare markets even more consolidated. Adding to the noise are a number of private lawsuits claiming that UHG and other major insurers are deliberately underpaying out-of-network providers to cut costs.
But it’s worth keeping perspective. The U.S. legal system is famously litigious, and class-action lawsuits, especially in healthcare, are nearly as common as hamburgers. The presence of legal action doesn’t necessarily mean there’s a strong case. So far, the DOJ hasn’t filed any formal antitrust charges in this area, which suggests that while the speculation is loud, the evidence may not be solid enough, at least not yet.
UHG has also been a target in several False Claims Act cases, where it’s been accused of not correcting inaccurate diagnosis codes that inflated government payments. While these cases continue to surface, UHG has successfully defended itself in some of the most high-profile ones, raising questions about the overall strength of the government’s arguments.
Whether any of these pressures lead to real legal consequences is still up in the air. But one thing is certain: UHG’s scale and influence mean it will remain at the center of the healthcare debate and under the watchful eye of regulators for the foreseeable future.
While opinions and speculation are easy to find, and it's clear that UnitedHealth Group is under an unusually bright spotlight, so far opinions and speculation is all that they are. The market has reacted to this negative sentiment - has the stock been oversold? Only time will tell.
The very fact that people are concerned about the size, scale and market dominance of UHG may in fact be good news for its shareholders - it certainly did Microsoft, Google and Apple no harm!